RxDoctor Payments Data

William Rizzo

Clinical Genetics (M.D.) · Omaha, NENPI 1780635839

Payments from drug & device makers

$169,990in general payments, 2019–2025

Across 118 payments — averaging $1440.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biomarin Pharmaceutical Inc.$85K
  • Takeda Pharmaceuticals U.S.A., Inc.$64K
  • Sanofi US Services Inc.$11K
  • Mirum Pharmaceuticals, Inc.$4K
  • Ultragenyx Pharmaceutical Inc.$3K
  • Amgen$2K
  • plus $677 from 8 others

What the payments were for

  • Consulting fees$5,90058%
  • Speaking & faculty fees$1,77518%
  • Travel & lodging$8428%
  • Food & beverage$1,54715%
  • Education$561%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical genetics (m.d.) providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Other clinical genetics (m.d.) in Omaha

Where these figures come from

Is this you, or does something look wrong? →